Conmed (CNMD)
NYSE:CNMD
Want to see CNMD full AI Analyst Report?
Top Page
Conmed
(NYSE:CNMD)
Select Model
Select Model
Rating:57Neutral
Price Target:
$37.00
▼(-16.57% Downside)
Action:Reiterated
Date:05/21/26
The score is held back primarily by weakening recent financial performance (sharp TTM revenue decline and lower margins) and a bearish technical setup (price below key moving averages with negative MACD). These are partially offset by continued positive free cash flow and manageable leverage, reasonable valuation with a ~2.2% dividend yield, and a cautiously positive earnings outlook with raised organic growth guidance and steady full-year adjusted EPS guidance despite near-term cash flow and refinancing headwinds.
Positive Factors
Improving gross margins
A sustained gross margin above 55% driven by favorable product mix and FX provides durable operating leverage. Higher gross margins support profitability despite revenue pressure, enabling investment in growth platforms and protecting cash flow generation over the next several quarters.
Negative Factors
Sharp TTM revenue decline
A ~30% TTM revenue drop materially reduces operating leverage and raises questions about demand durability. Even with organic growth improving, the top‑line contraction compresses margins, reduces reinvestment capacity and lengthens the path to restoring historical profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving gross margins
A sustained gross margin above 55% driven by favorable product mix and FX provides durable operating leverage. Higher gross margins support profitability despite revenue pressure, enabling investment in growth platforms and protecting cash flow generation over the next several quarters.
Read all positive factors
Conmed (CNMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.07B
Dividend Yield2.02%
Average Volume (3M)368.83K
Price to Earnings (P/E)19.9
Beta (1Y)0.68
Revenue Growth4.78%
EPS Growth-53.80%
CountryUS
Employees3,900
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.77
Shares Outstanding30,109,194
10 Day Avg. Volume284,080
30 Day Avg. Volume368,831
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.22
Price to Sales (P/S)0.92
P/FCF Ratio8.35
Enterprise Value/Market Cap1.77
Enterprise Value/Revenue1.39
Enterprise Value/Gross Profit2.59
Enterprise Value/Ebitda8.99
Forecast
1Y Price Target
$39.39Price Target Upside-11.18% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)4.36
Revenue Forecast (FY)$1.36B
Conmed Business Overview & Revenue Model
Company Description
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tiss...
How the Company Makes Money
CONMED makes money primarily by selling medical devices and related consumables used in surgical procedures. Its revenue model is largely product-sales driven: (1) single-use/disposable items and procedure-based consumables (e.g., accessories and ...
Conmed Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 29, 2026
Earnings Call Sentiment Neutral
The call presented a mixed but constructive view: near‑term headwinds included modest revenue declines on a reported basis, lower adjusted net income and EPS, weaker cash from operations and higher working capital as inventory was intentionally built. Offsetting these concerns were upgraded organic revenue guidance (5.0%–6.5%), clear momentum in core growth platforms (AirSeal, Buffalo Filter direct smoke, BioBrace), improved gross margin (up 100 bps) and maintained full‑year adjusted EPS guidance despite a planned refinancing headwind. Management also completed GI divestitures to focus resources and continued buybacks. Overall the transcript shows cautious optimism with tangible operational and strategic progress balanced against short‑term financial pressures.Positive Updates
Raised Organic Revenue Guidance
Organic revenue guidance for FY2026 was raised to 5.0%–6.5% (from prior 4.5%–6.0%), with FX now expected to be a ~40–50 bps tailwind; reported 2026 revenue guidance increased at the low end to $1.35B–$1.375B and Q2 revenue is expected to be $336M–$340M.
Negative Updates
Total Sales and GI Exit Impact
Total sales were $317M in Q1 (Pat) with a reported decrease of 1.3% YoY (Todd reported total sales down 2.9% YoY); divestiture of GI product lines reduced comparable revenue but organic sales grew 2.1% YoY (organic excludes GI).
Read all updates
Q1-2026 Updates
Positive
Negative
Raised Organic Revenue Guidance
Organic revenue guidance for FY2026 was raised to 5.0%–6.5% (from prior 4.5%–6.0%), with FX now expected to be a ~40–50 bps tailwind; reported 2026 revenue guidance increased at the low end to $1.35B–$1.375B and Q2 revenue is expected to be $336M–$340M.
Read all positive updates
Company Guidance
CONMED raised its 2026 organic revenue growth outlook to 5.0%–6.5% (from 4.5%–6.0%), now expects reported revenue of $1.35B–$1.375B (Q2 revenue $336M–$340M), and reiterated adjusted EPS guidance of $4.30–$4.45 for the year while guiding Q2 adjusted EPS of $1.09–$1.14; foreign exchange is expected to be a 40–50 bps tailwind, AirSeal and direct smoke are still expected to grow in the high single-digit to low double‑digit range for the full year, and GI revenue for 2026 is now forecast at $14.5M–$17.5M (versus the prior $21M–$25M estimate, ~ $7M lower at the midpoint) with corresponding cost reductions; the company plans to refinance debt in Q2 with bank financing (eschewing new convertibles), which could increase full‑year adjusted interest expense and depress adjusted EPS by at least $0.10, yet operating cash flow is still forecast at $145M–$155M, capital expenditures $20M–$30M, free cash flow around $125M, and management expects to maintain ~3x leverage while continuing share repurchases (Q1 buybacks ~858k shares for $37.4M).Conmed Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
63
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37B | 1.37B | 1.31B | 1.24B | 1.05B | 1.01B |
| Gross Profit | 735.25M | 725.38M | 733.03M | 676.25M | 571.25M | 568.04M |
| EBITDA | 211.37M | 193.47M | 272.18M | 192.48M | 7.80M | 179.33M |
| Net Income | 54.85M | 47.05M | 132.42M | 64.46M | -80.58M | 62.54M |
Balance Sheet | ||||||
| Total Assets | 2.31B | 2.33B | 2.31B | 2.30B | 2.30B | 1.77B |
| Cash, Cash Equivalents and Short-Term Investments | 35.03M | 40.82M | 24.46M | 24.30M | 28.94M | 20.85M |
| Total Debt | 860.87M | 834.94M | 905.78M | 991.25M | 1.05B | 684.66M |
| Total Liabilities | 1.30B | 1.29B | 1.34B | 1.47B | 1.55B | 980.58M |
| Stockholders Equity | 1.02B | 1.03B | 962.68M | 834.22M | 745.54M | 785.43M |
Cash Flow | ||||||
| Free Cash Flow | 123.71M | 150.88M | 153.88M | 106.32M | 11.58M | 96.90M |
| Operating Cash Flow | 142.63M | 170.69M | 166.97M | 125.35M | 33.37M | 111.77M |
| Investing Cash Flow | -13.92M | -20.96M | -13.08M | -20.03M | -249.53M | -14.87M |
| Financing Cash Flow | -129.97M | -135.82M | -151.00M | -110.43M | 225.00M | -101.55M |
Conmed Technical Analysis
Negative
44.35
Price Trends
36.67
Negative
39.10
Negative
42.73
Negative
Market Momentum
-0.36
Positive
44.94
Neutral
21.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNMD, the sentiment is Negative. The current price of 44.35 is above the 20-day moving average (MA) of 36.34, above the 50-day MA of 36.67, and above the 200-day MA of 42.73, indicating a bearish trend. The MACD of -0.36 indicates Positive momentum. The RSI at 44.94 is Neutral, neither overbought nor oversold. The STOCH value of 21.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNMD.
Conmed Risk Analysis
Conmed disclosed 37 risk factors in its most recent earnings report. Conmed reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Conmed Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $1.70B | 24.76 | 16.61% | ― | 11.19% | 7.61% | |
57 Neutral | $1.07B | 19.91 | 5.40% | 2.02% | 4.78% | -53.80% | |
54 Neutral | $1.08B | 91.25 | 2.66% | ― | 17.59% | ― | |
54 Neutral | $1.25B | -2.49 | -47.65% | ― | 1.24% | -1605.54% | |
54 Neutral | $1.38B | -17.27 | -5.11% | ― | 1.24% | -202.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.50B | -14.52 | -27.70% | ― | 29.26% | -7.59% |
* Healthcare Sector Average
CNMD
Conmed
35.70
-19.27
-35.05%
AORT
Artivion
22.19
-6.52
-22.71%
IART
Integra Lifesciences
16.04
3.72
30.19%
UFPT
Ufp Technologies
220.10
-12.10
-5.21%
AHCO
AdaptHealth
10.13
1.38
15.77%
PRCT
PROCEPT BioRobotics
26.33
-31.61
-54.56%
Conmed Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Conmed strengthens board with new independent directors
Positive
May 20, 2026
On May 19, 2026, CONMED’s board moved to expand its governance and leadership structure, increasing the board to nine directors and appointing industry veterans Celine Martin and Jeff Mirviss as independent non‑employee directors effec...
Executive/Board ChangesRegulatory Filings and Compliance
Conmed Names Andrew Moller Interim Principal Financial Officer
Positive
Mar 13, 2026
On March 13, 2026, CONMED Corporation announced that Andrew Moller, 51, will be appointed Interim Principal Financial Officer effective March 15, 2026, following his prior roles as Vice President, Corporate Controller and Principal Accounting Offi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.